Request Info


Ask for our annual reports or more information
Email Us

Email Alerts

Sign up for email alerts
Email Alerts
Investor Relations

News Releases

RSS RSS Feeds
News Release Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998
DateTitle  
12/10/2008Meridian Bioscience to Participate in Panel Presentation at RBC Capital Markets 2008 Healthcare Conference
CINCINNATI--(BUSINESS WIRE)--Dec. 10, 2008--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that Jack Kraeutler, Chief Executive Officer, will be presenting as a panel participant at the RBC Capital Markets 2008 Healthcare Conference, held at the Westin Times Square Hotel in New York. The panel titled, Getting to the Point (of Care) is scheduled from 9-9:55 a.m. ET. on December 11, 2008 in Panel Room 2. The information prov... 
 Printer Friendly Version
12/2/2008Meridian Bioscience Announces Filing of Shelf Registration Statement to Replace Expiring Registration Statement
CINCINNATI--(BUSINESS WIRE)--Dec. 2, 2008--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced it has filed a shelf registration statement on Form S-3 with the US Securities and Exchange Commission. This registration statement replaces the Company's existing shelf registration statement originally filed in September 2003 which was scheduled to expire on December 1, 2008. This unlimited shelf registration includes common stock, preferre... 
 Printer Friendly Version
11/17/2008Meridian Bioscience to Present at theLazard Capital Markets 5th Annual Healthcare Conference
CINCINNATI, Nov 17, 2008 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that the Company has been invited to present at the Lazard Capital Markets 5th Annual Healthcare Conference on Tuesday, November 18, 2008 at 8:55 a.m. ET at The St. Regis, New York. Melissa Lueke, Vice President, CFO, is scheduled to present. A question and answer session will follow the Company's presentation. The information prov... 
 Printer Friendly Version
11/12/2008Meridian Bioscience Reports Record Fiscal 2008 Operating Results, Increases Regular Cash Dividend Rate, and Reaffirms Guidance
CINCINNATI--(BUSINESS WIRE)--Nov. 12, 2008--Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported record fourth quarter and full-year fiscal 2008 net sales of $36.5 million and $139.6 million, respectively, increases of 13% and 14%, respectively, over the same periods of the prior fiscal year; reported record fourth quarter and full-year fiscal 2008 ... 
 Printer Friendly Version
10/30/2008New Molecular Test for C. difficile from Meridian Bioscience Expected to be Launched in Fiscal Year 2009
CINCINNATI--(BUSINESS WIRE)--Oct. 30, 2008--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced, in conjunction with the Association for Molecular Pathology 2008 Annual Meeting now occurring in Grapevine, Texas, that it anticipates launching a simple, rapid new molecular test for the toxin-producing forms of the C. difficile bacteria in the second half of fiscal year 2009. This innovative molecular test is based upon Loop Mediated Isothermal Amplification (LAMP)... 
 Printer Friendly Version
10/1/2008Meridian Bioscience to Present at the William Blair and Company Small-Cap Growth Stock Conference
CINCINNATI--(BUSINESS WIRE)-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that the Company has been invited to present at the William Blair and Company Small-Cap Growth Stock Conference on Tuesday, October 7, 2008 at 12:00 p.m. ET at the Waldorf-Astoria Hotel, New York. Jack Kraeutler, Chief Executive Officer, is scheduled to present. A question and answer session will follow the Company's presentation. The information provided during the session may n... 
 Printer Friendly Version
9/23/2008Meridian Bioscience to Present at the 2008 UBS Global Life Science Conference
CINCINNATI, Sep 23, 2008 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that the Company has been invited to present at the 2008 UBS Global Life Science Conference at the Grand Hyatt New York in New York City. Jack Kraeutler, CEO, is scheduled to present on Wednesday, September 24, 2008 at 1:30 p.m. ET. A question and answer session will follow and some of the information provided during the session may not ... 
 Printer Friendly Version
9/10/2008Meridian Bioscience Announces New Exclusive Canadian Distribution Agreement with Somagen Diagnostics
CINCINNATI--(BUSINESS WIRE)--Sept. 10, 2008--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced the commencement of a new exclusive Canadian distribution agreement with Somagen Diagnostics, Edmonton, Alberta. This decision is consistent with Meridian's stated commitment to expand its non-US businesses. Somagen Diagnostics, www.somagen.com, focuses on niche markets within the clinical diagnostic market. Like Meridian, Somagen targets markets where they can... 
 Printer Friendly Version
9/5/2008Meridian Bioscience to Present at the Robert W. Baird 2008 Small Cap Healthcare Conference
CINCINNATI--(BUSINESS WIRE)--Sept. 5, 2008--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that the Company has been invited to present at the Robert W. Baird 2008 Small Cap Healthcare Conference on Wednesday, September 10, 2008 at 12:50 p.m. ET at the Intercontinental The Barclay New York. Jack Kraeutler, Chief Executive Officer, is scheduled to present. A question and answer session will follow the Company's presentation. The information provided during t... 
 Printer Friendly Version
8/14/2008Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2009 and Reaffirms Fiscal 2008 Guidance
CINCINNATI--(BUSINESS WIRE)--Aug. 14, 2008--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company's fiscal 2009 sales and earnings estimates. Based on the Company's business planning and budgeting activities for the fiscal year ending September 30, 2009, management expects net sales to be in the range of $157 to $160 million and per share diluted earnings to be between $0.86 and $0.90. The per share estima... 
 Printer Friendly Version
7/17/2008Meridian Bioscience Reports Record Operating Results, Declares Regular Cash Dividend, Reaffirms Fiscal 2008 Guidance, and Comments on Fiscal 2009 Outlook
CINCINNATI--(BUSINESS WIRE)--July 17, 2008--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: -- reported record third quarter and nine-month sales of $33.1 million and $103.2 million, respectively, increases of 11% and 14% over the same periods of the prior fiscal year; -- reported record third quarter and nine-month operating income of $11.0 million and $32.9 million, respectively, increases of 16% and 25% over the same... 
 Printer Friendly Version
6/25/2008Fortune Small Business Lists Meridian Bioscience as One of America's Fastest-Growing Small Companies
CINCINNATI, June 25, 2008 (PRIME NEWSWIRE) -- Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that FORTUNE Small Business has ranked Meridian Bioscience, Inc. number 65 on its eighth annual FSB 100 list of the fastest-growing small public companies in America. The list appears in the July/August issue of FORTUNE Small Business and is available online at http://money.cnn.com/magazines/fsb/fsb100/2008/ John A. Kraeutler, Chief Executive Officer, stated, The development, manufacture an... 
 Printer Friendly Version
6/19/2008Meridian Bioscience Completes Acquisition of Recombinant Protein Technologies and Products from Vybion, Inc.
CINCINNATI--(BUSINESS WIRE)--June 19, 2008--Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced it has completed the purchase of technologies and products including infectious disease recombinant proteins and cardiac antigens from Vybion, Inc., highlights include: -- year 1 revenues of approximately $400,000 with attractive margins post-integration; -- purchase price of $653,000 in cash plus future royalties based on net sales of the acquired product... 
 Printer Friendly Version
5/13/2008Meridian Signs Agreement in Principle to Acquire Line of Recombinant Proteins from Vybion, Inc.
CINCINNATI--(BUSINESS WIRE)--May 13, 2008--Meridian Bioscience, Inc. Cincinnati, Ohio (NASDAQ: VIVO) today announced it has executed a letter of intent to acquire a line of infectious disease recombinant proteins and cardiac antigens from Vybion, Inc. The purchase price includes cash and future royalties based on net sales of the acquired products, the amounts of which were not disclosed. The assets to be acquired include a portfolio of recombinant viral proteins and cardiac antigens,... 
 Printer Friendly Version
5/12/2008Meridian Bioscience to Present At the Nasdaq 21st Investor Program, London
CINCINNATI, May 12, 2008 (PrimeNewswire via COMTEX News Network) -- Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that the Company has been invited to present at the NASDAQ 21st Investor Program, London on Wednesday, May 21, 2008 at 11:15 a.m. BST at The Andaz Hotel, London, UK. Bill Motto, Executive Chairman of the Board and Jack Kraeutler, Chief Executive Officer, are scheduled to present. A question and answer session will follow the Company's presentation. The information provided ... 
 Printer Friendly Version
5/12/2008Meridian Bioscience to Present at the Robert W. Baird 2008 Growth Stock Conference
CINCINNATI--(BUSINESS WIRE)--May 12, 2008--Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that the Company has been invited to present at the Robert W. Baird 2008 Growth Stock Conference on Wednesday, May 14, 2008 at 3:05 p.m. CDT at the Four Seasons Hotel in Chicago. Bill Motto, Executive Chairman of the Board and Jack Kraeutler, Chief Executive Officer, are scheduled to present. A question and answer session will follow the Company's presentation. The information provided ... 
 Printer Friendly Version
4/17/2008Meridian Bioscience Reports Record Second Quarter and Six Months Operating Results
CINCINNATI--(BUSINESS WIRE)--April 17, 2008--Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: -- reported record second quarter and six months net sales of $36.2 million and $70.1 million, respectively, increases of 13% and 15% over the same periods of the prior fiscal year; -- reported record second quarter and six months net earnings of $7.3 million and ... 
 Printer Friendly Version
4/9/2008Meridian Bioscience Launches Two New TRU(TM) Brand Rapid Tests for the Detection of Epstein-Barr Virus
CINCINNATI--(BUSINESS WIRE)--April 9, 2008--Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has launched two new rapid tests for Epstein-Barr Virus (EBV): TRU EBV-M(TM) and TRU EBV-G(TM). The TRU EBV tests are the first rapid tests on the market which employ recombinant antigen technology to detect IgM and IgG antibodies specific to EBV. EBV is the primary cause of infectious mononucleosis and has been implicated in a number of benign and malignant disorders, incl... 
 Printer Friendly Version
3/25/2008Meridian Bioscience to Present at the Sidoti & Company, LLC Twelfth Annual New York Emerging Growth Institutional Investor Forum
CINCINNATI--(BUSINESS WIRE)--March 25, 2008--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that the Company has been invited to present at the Sidoti & Company, LLC Twelfth Annual New York Emerging Growth Institutional Investor Forum at The Hyatt Regency Hotel in New York. Jack Kraeutler, Chief Executive Officer, is scheduled to present on Wednesday, March, 26, 2008 at 1:30 p.m. ET. A question and answer session will follow and some of the information prov... 
 Printer Friendly Version
1/28/2008Meridian Bioscience Promotes John A. Kraeutler to Chief Executive Officer, William J. Motto Moves to Executive Chairman
CINCINNATI--(BUSINESS WIRE)--Jan. 28, 2008--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that the Board of Directors has appointed Jack Kraeutler to Chief Executive Officer. Mr. Kraeutler joined the Company in January, 1992 as Executive Vice President and Chief Operating Officer. In July 1992, Mr. Kraeutler was named President and Chief Operating Officer of Meridian. Before joining Meridian, Mr. Kraeutler served as Vice President, General Manager for a di... 
 Printer Friendly Version
1/22/2008Meridian Bioscience Reports Record First Quarter Sales and Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2008 Guidance
CINCINNATI--(BUSINESS WIRE)--Jan. 22, 2008--Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS ---------------------------------------------------------------------- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: -- reported record first quarter net sales of $33.8 million an 18% increase over the same period of the prior fiscal year; -- reported record quarterly net earnings of $7.5 million, a 34% ... 
 Printer Friendly Version